Connect with us

Politics

Lawmakers Slam Attorney General Over Improper Marijuana Investigations Alleged By Whistleblower

Published

on

Several members of a key congressional committee on Wednesday expressed concerns over a Justice Department whistleblower’s allegations that the attorney general directed multiple improper antitrust investigations into marijuana business mergers because of his personal opposition to the industry.

Reps. Steve Cohen (D-TN), Pramila Jayapal (D-WA) and Mary Gay Scanlon (D-PA) each directly questioned the witness, John Elias, about the allegations at a hearing that also covered other unrelated reports of inappropriate actions by Attorney General William Barr.

The lawmakers touched on the costs of the cannabis investigations to taxpayers, the waste of department resources to conduct the inquiries and the attorney general’s apparent animus toward businesses operating in accordance with state legalization laws.

“Did that cost the cannabis folks a lot of money?” Cohen asked.

“Absolutely, these subpoenas that get issued that require production of millions of documents is very burdensome,” Elias, who has been with the Justice Department for 14 years, said.

“So it was harassment by Bill Barr of an industry he didn’t like, is that right?” the congressman followed up.

The witness replied that “I think that’s a fair way to characterize it, yes.”

“Barr doesn’t like marijuana. Marijuana is seven times more likely to be enforced against young African Americans, breeding discontent with police and breeding interactions with police, and Barr doesn’t care about that type of stuff because he doesn’t like marijuana,” Cohen said. “That’s one of the breeding grounds of distrust of African Americans and police and police and African American contact and problems. Very unfortunate.”

Later in the hearing, Elias disclosed in response to a question from Scanlon that a second, unnamed Justice Department whistleblower had similarly raised concerns about the Antitrust Division’s marijuana investigations that were reportedly made at the attorney general’s behest. He further said that the response to his complaint was troubling because the Office of Professional Responsibility (OPR) determined that even if the investigations were directed out of personal animus, that would not represent a violation of any rule.

“That’s very concerning to me because it seems so self-evident that if your sole motivation is animosity that that’s impermissible,” he said.

Rep. Lou Correa (D-CA) wasn’t able to attend the House Judiciary Committee hearing, but his office shared a copy of his prepared statement on the subject with Marijuana Moment. He said it was unacceptable that the allegedly improper cannabis-related investigations accounted for nearly one-third of the Antitrust Division’s caseload in 2019.

“After nearly four years, I did not think the actions of this administration could continue to shock me,” he said. “John Elias’s testimony showed me just how wrong that was. The very idea that the lead law enforcement professional in the land would use the immense power of the United States government to investigate American businesses out of his own personal animosity should put fear into every American.”

“Due process and equal protection under the law are the cornerstones of our democracy,” he added. “When they crumble, the fabric of our democracy and legal system follows close behind.”

Correa noted the growing number of states that have legalized cannabis in some form and “yet the federal government repeatedly treats this legal industry as criminals and second-class businesses.”

“The attorney general’s blatant abuse of his authority to improperly investigate cannabis businesses shows just how important it is to end the federal prohibition of cannabis,” he said. “Regardless of Mr. Barr’s own personal feelings, Americans wildly support descheduling cannabis, and it is time  ur federal laws represented the people’s will.”

“Attorney General Barr has once again shown he cannot be trusted to meet the high standards of his position. His use of the Department of Justice Antitrust Division to satisfy his own personal grudges are beyond reproach. If these allegations stand true, there must be serious consequences for the Attorney General. Every American must know with full confidence that the leader of American law enforcement will protect each of our constitutional right to due process and equal protection under the law. When investigations by the Department of Justice can be directed by the personal whims of individual men, the very core of our legal system shattered.”

Jayapal stressed that the allegations indicate the Justice Department’s resources and taxpayer dollars were wasted at the whim of the nation’s top prosecutors. She first asked how much of the division’s staff was involved in the investigations.

“Congresswoman, there were dozens of staff—attorneys, paralegals, economists and others who worked on these various cases,” Elias replied.

Jayapal also pressed the witness on the extent to which the millions of documents that were obtained over the course of the investigations were reviewed.

“I think a very small number of the documents were reviewed,” he said, adding that many were “uploaded after the closing process had been initiated as if they were irrelevant to the investigation.”

Ultimately, across 6 of the 10 investigations for which data are available, 5,965,000 documents were produced by the marijuana companies under inquiry.

“So they requested enormous resources, taxpayer dollars were used, these documents were never really looked at, they weren’t relevant to the investigations—and so to be clear, at Attorney General Barr’s direction, the department expends countless taxpayer resources to force companies to ultimately produce millions of pages of evidence and then doesn’t even look at or upload some of that evidence before admitting there’s a violation,” Jayapal said.

“Have you ever seen anything this extreme?” she asked.

“In my experience, which includes 14 years at the Justice Department at many different levels of the antitrust division, no, I have never seen anything like that,” the witness said.

Asked why the situation is concerning to him, Elias said it’s “concerning because the investigations and the work of the Antitrust Division need to be done in good faith—they need to be done evenhandedly—both for the sake of everybody involved and for the sake of the public’s perception of the rule of law in that the Justice Department is being aboveboard with everything.”

“For it to disregard the usual standards in the law on what counts for an antitrust investigation is improper and an abuse,” he said.

Early in the hearing, Rep. Doug Collins (R-GA) mentioned that the Justice Department’s OPR had determined that the investigations into cannabis mergers didn’t violate rules or regulations and questioned his political motivations. He also brought up marijuana’s legal status under federal law and asked the witness whether he knew what schedule the plant is classified as under the Controlled Substances Act.

Elias said he knew it was a controlled substance but wasn’t sure of the schedule.

“You were part of an antitrust in marijuana and didn’t know how it was scheduled?” Collins said. “The credibility of this is going downhill quickly here.”

Other committee members, including Rep. Greg Stanton (D-AZ), spoke more broadly about the Justice Department’s antitrust investigations without explicitly discussing the marijuana merger inquiries. He said the department’s “resources are not being used to protect the American people” when it is “pursuing meritless investigations.”

All of these questions come one day after Elias’s written testimony was first released, detailing how the attorney general directed questionable investigations into 10 mergers of state-legal marijuana companies, including one for MedMen and PharmaCann that seemed to have resulted in the end of the agreement.

“The head of the Antitrust Division, Assistant Attorney General Delrahim, responded to internal concerns about these investigations at an all-staff meeting on September 17, 2019,” the witness said. “There, he acknowledged that the investigations were motivated by the fact that the cannabis industry is unpopular ‘on the fifth floor,’ a reference to Attorney General Barr’s offices in the DOJ headquarters building.”

“Personal dislike of the industry is not a proper basis upon which to ground an antitrust investigation,” he said.

Barr’s personal opposition to the cannabis industry doesn’t seem to comport with statements he’s made in various congressional hearings, where he’s expressed interest in resolving the state-federal conflict over marijuana policy.  Last year, he said that while he personally opposes legalization, he would prefer for Congress to pass a bill respecting the rights of states to implement their own cannabis policies rather than maintain blanket federal prohibition.

Federal Commission Pushes Expansion Of Marijuana And Psychedelics Research For Military Veterans

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Ohio Marijuana Activists Launch Ballot Campaign To Push Lawmakers To Enact Legalization

Published

on

Ohio marijuana activists have a new plan to legalize cannabis in the state as lawmakers pursue separate reform legislation.

Voters rejected a 2015 legalization initiative, and advocates suspended a campaign to place another measure on the 2020 ballot due to the coronavirus pandemic. But on Tuesday, the Coalition to Regulate Marijuana Like Alcohol (CTRMLA) launched a new effort to implore legislators to enact the policy change.

The group submitted the requisite 1,000 signatures to the Ohio attorney general’s office on Tuesday. Officials now have 10 days to review the summary and text to ensure that it is “fair and truthful” and approve it for circulation. Several existing medical cannabis businesses are backing the measure.

“I think people are tired of prohibition with respect to marijuana,” spokesperson Tom Haren told Marijuana Moment in a phone interview on Tuesday, adding that he thinks Ohioans are ready to join the growing list of states that are enacting legalization.

Unlike past efforts, the new measure is a statutory, rather that a constitutional, proposal. If supporters collect 132,887 valid signatures from registered voters, the legislature will then have four months to adopt the measure, reject it or adopt and amended version. If lawmakers to not pass the proposal, organizers will then need to collect an additional 132,887 signatures to place the measure before voters on the ballot in 2022.

“We are proposing to regulate marijuana for adult use, just like we do for alcohol,” Haren said in a press release. “Our proposal fixes a broken system while ensuring local control, keeping marijuana out of the hands of children and benefiting everyone.”

The proposed law that CTRMLA is pushing would legalize possession of up to 2.5 ounces of cannabis for adults 21 and older, and they could also have up to 15 grams of marijuana concentrates. Individuals could grow up to six plants for personal use, with a maximum 12 plants per household.

It’s a notable departure from the failed 2015 reform initiative, which faced criticism from advocates because of an oligopolistic model that would’ve granted exclusive control over cannabis production to the very funders who paid to put the measure on the ballot.


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

A 10 percent sales tax would be imposed on cannabis sales, with revenue being divided up to support social equity and jobs programs (36 percent), localities that allow adult-use marijuana enterprises to operate in their area (36 percent), education and substance misuse programs (25 percent) and administrative costs of implementing the system (three percent).

Under the proposal, a Division of Cannabis Control would be established under the state Department of Commerce. It would have authority to “license, regulate, investigate, and penalize adult use cannabis operators, adult use testing laboratories, and individuals required to be licensed.”

The measure gives current medical cannabis businesses a head start in the recreational market. Regulators would need to begin issuing adult-use licenses to qualified applicants who operate existing medical operations within nine months of the enactment of the legislation.

The division would also be required to issue 40 recreational cultivator licenses and 50 adult-use retailer licenses “with a preference to applications who are participants under the cannabis social equity and jobs program.” And it would authorize regulators to issue additional licenses for the recreational market two years after the first operator is approved.

Individual municipalities would be able to opt out of allowing new recreational cannabis companies from opening in their area, but they could not block existing medical marijuana firms even if they want to add co-located adult-use operations. Employers could also maintain policies prohibiting workers from consuming cannabis for adult use.

Further, regulators would be required to “enter into an agreement with the Department of Mental Health and Addiction Services” to provide “cannabis addiction services,” which would involve “education and treatment for individuals with addiction issues related to cannabis or other controlled substances including opioids.”

“Marijuana legalization is an issue whose time has come in Ohio,” Haren said in the press release, adding that “we crafted legislation based on the best practices learned by those that went before us.”

“Ohioans want this,” he said. “They see marijuana legalization as inevitable. They want our leaders to seize the opportunity and take control of our future.”

With respect to social equity, some advocate are concerned about the lack of specific language on automatic expungements to clear the records of people with convictions for offenses that would be made legal under the legislation. That said, it does include a provision requiring regulators to “study and fund” criminal justice reform initiatives including expungements.

Haren said the reason they weren’t able to prescribe specific expungement provisions is due to the state’s single subject ballot rule for initiated statutes.

If the measure does make the ballot, the results of local reform initiatives across the state signal that it would be successful.

As it stands, 22 jurisdictions have adopted local statues so far that reduce the penalty for low-level cannabis possession from a misdemeanor punishable by jail time and a fine to the “lowest penalty allowed by state law.” And activists are pursuing similar policy changes in dozens of cities this year, with several having already collected enough signatures to qualify for local ballots.

“Legalization is popular in Ohio,” Haren told Marijuana Moment. “That’s why these types of local decrim measures are passing—because people recognize that marijuana prohibition has failed, and it’s not good policy. And it’s much better policy to have a regulated market that provides consumers with an ability to purchase from a legal, regulated source.”

Meanwhile, state Rep. Casey Weinstein (D) recently announced he will be sponsoring legislation alongside Rep. Terrence Upchurch (D) this session that would legalize and regulate marijuana in the state. It would mark the first time such a proposal to allow recreational cannabis commerce has been introduced in the legislature

“Ohioans and Americans are way out ahead on this issue, and the comfort level with first decriminalization and medical marijuana and then full legalization is just so far beyond where legislators are,” Weinstein told Marijuana Moment in a phone interview about his bill. “This is an effort to close that gap and catch up.”

Haren said that while he hasn’t reviewed Weinstein’s legislation at this point, his organization would welcome working with any lawmaker to get reform enacted one way or the other.

Weinstein’s bill would would legalize possession of up to five ounces of cannabis for adults 21 and older and allow them to cultivate up to 12 plants for personal use. It will also include provisions to expunge prior convictions for possession and cultivation activities that are being made legal under the measure.

Like the CTRMLA proposal, a 10 percent excise tax would be imposed on marijuana sales. But after covering administrative costs, revenue would be divided among municipalities with at least one cannabis shop (15 percent), counties with at least one shop (15 percent), K-12 education (35 percent) and infrastructure (35 percent).

Gov. Mike DeWine (R) is likely to oppose the legislative effort given his record. But a voter-led initiative could create a different opportunity for advocates.

“We are laser focused at this point on getting the required number of signatures, sending it to the legislature and then working with them—hand in glove, in lockstep, whatever phrase you want to use—to get get this proposal ultimately signed into law by the governor,” Haren said.

According to cleveland.com, the CTRMLA campaign has already hired several prominent consulting firms to work on the effort, suggesting it has robust funding.

Massachusetts Lawmakers Discuss Bill To Create Psychedelics Legalization Task Force At Hearing

Photo courtesy of Philip Steffan.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Massachusetts Lawmakers Discuss Bill To Create Psychedelics Legalization Task Force At Hearing

Published

on

Massachusetts lawmakers on Tuesday heard testimony about a bill to create a task force charged with studying the implications of legalizing psychedelics like psilocybin and ayahuasca.

The legislature’s Joint Judiciary Committee met to discuss legislation from Rep. Mike Connolly (D). While members didn’t vote on the proposal, the sponsor was able to make the case for the reform, noting the emerging research that suggests entheogenic substances hold significant therapeutic potential for certain mental health conditions.

He also pointed to the local reform movement that’s led three Massachusetts cities to decriminalize psychedelics so far, saying it represents “another reason why it should be a priority for all of us to bring stakeholders together and have that conversation about what policies should look like.”

“We’re hearing from the medical community, we’re hearing from clinicians and researchers that the potential benefits here simply can’t be ignored,” Connolly said. “There are these issues like PTSD and depression, anxiety and addiction that…we are struggling to address, and what the research is telling us is that these substances offer a tremendous benefit.”

The 21-member task force that the lawmaker is proposing would be responsible for analyzing the pros and cons of “legalizing the possession, consumption, transportation and distribution of naturally cultivated entheogenic plants and fungi.”

The sponsor said on Tuesday that the group “could really allow Massachusetts to play a leadership role in crafting policies around these substances.”

In an email to Marijuana Moment, Connolly said that momentum for broader psychedelics and drug policy reform in states across the country shows that “our proposal to create a task force to craft policies around legalization is rational and warranted.”

“Given our status as a longtime leader in civil rights, freedom, academic research and advances in medicine,” he said, “it is important for the Commonwealth of Massachusetts to be proactive about crafting policies to ensure that as the movement for legalization of psychedelics continues to advance—and as the clinical trials showing the therapeutic value of these medicines continue to pile up—that we are moving forward in an equitable, just and inclusive fashion.”


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Middlesex District Attorney Marian Ryan also testified in favor of the reform proposal before the committee on Tuesday.

For the most part, the burgeoning psychedelics reform movement has been limited to decriminalization—with the exception or Oregon, where voters elected to legalize psilocybin for therapeutic purposes during last year’s election. California activists are also pushing to place psilocybin legalization on the state’s 2022 ballot as a lawmaker works to pass a separate bill to legalize possession of a wide range of psychedelics that has already passed the state Senate and two Assembly committees.

While the Massachusetts legislation would only establish a task force to investigate the potential legalization of these substances, it marks another significant development demonstrating how local reforms have caught the attention of state legislators.

Connolly said at Tuesday’s hearing that it’s important to remember “that it was the Nixon administration in the 1970s that classified entheogens as Schedule I substances, without any real scientific basis. It was more to do with politics—it was more to do with systemic racism—that led to this classification and this criminalization.”

“Today, when you hear some of the professionals, some of the researchers talk about this, they really feel like we lost several decades of potential therapeutic benefit because of these arbitrary political decisions,” he said. “With this task force, there really is an opportunity for us in Massachusetts to bring policymakers and stakeholders together to make sure that as this research advances we can be ready with applicable policies, so don’t don’t repeat the mistakes of the past.”

The lawmaker said “the war on drugs, racial injustice and years of oppression here in our country” partly motivated the introduction of his legislation.

The task force would “bring together stakeholders from the scientific, public safety, racial justice, harm reduction, indigenous, social work, the relevant regulatory bodies and medical communities to make recommendations for the legalization and possession, consumption and distribution of entheogenic substances,” he said.

Three Massachusetts cities—Northampton, Somerville and Cambridge—have each passed resolutions to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics and other drugs.

“I’m proud to represent Somerville and Cambridge, two communities that have acted in recent months to decriminalize the possession of psychedelics and entheogenic plans, primarily as part of the larger movement to continue working to undo the racist impact of the War On Drugs,” Connolly told Marijuana Moment.

If his bill is enacted, the 21-person task force would have until June 2022 to study the effects of plant- and fungi-based psychedelics and develop recommendations for how to legalize the substances “in a manner that maximizes equitable access and sustainable manufacture of these plants.”

Particular focus would be paid under the bill to the impact of drug prohibition on on marginalized groups, “including indigenous people, veterans, people with physical and mental health disabilities, Black people, people of Latino and Hispanic heritage, people of Asian descent, people of color, people in poverty, and people identifying with the LGBTQ community.”

The measure also calls for the task force to develop recommendations around “pardons, parole, diversion, expungement, and equity measures” for people with criminal records due to possession, or distribution of controlled substances.

The Massachusetts developments are some of the latest iterations of a national psychedelics reform movement that’s spread since Denver became the first city to decriminalize psilocybin mushrooms in 2019.

Besides the cities in Massachusetts, four others—Oakland, Santa Cruz, Ann Arbor and Washington, D.C.—have also decriminalized possession of plant-and fungi-based psychedelics.

An Arcata, California councilmember announced this month that she would sponsor a measure to decriminalize psychedelics. That measure has since been referred to a committee.

The governor of Connecticut signed legislation recently that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.

Texas also recently enacted a bill to require the state study the medical benefits of psychedelics for military veterans.

A New York lawmaker introduced a bill last month that would require the state to establish an institute to similarly research the medical value of psychedelics.

In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.

After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor recently announced that his office will not be pursuing charges over possessing entheogenic plants and fungi—“regardless of the amount at issue.”

The Aspen, Colorado City Council discussed the therapeutic potential of psychedelics like psilocybin and proposals to decriminalize such substances at a meeting in May. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.

Seattle lawmakers also recently sent a letter to members of a local task force focused on the opioid overdose epidemic, imploring the group to investigate the therapeutic potential of psychedelics like ayahuasca and ibogaine in curbing addiction.

The psychedelics conversation is also catching on at the federal level.

The U.S. House of Representatives will vote this week on a proposal from Rep. Alexandria Ocasio-Cortez (D-NY) that remove a spending bill rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine.

In 2019, a large majority of Democratic House members joined all but seven Republicans in a vote against an earlier version of the congresswoman’s amendment. But given the surge in state and local psychedelics reform efforts in the years since, it stands to reason that this Congress may take the issue more seriously this time.

Federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions, a report attached to separate spending legislation that’s part of an advancing minibus package says.

When it comes to broader drug policy reform, Oregon voters also approved an initiative in November to decriminalize possession of all drugs. This year, the Maine House of Representatives passed a drug decriminalization bill, but it later died in the Senate.

Last month, lawmakers in Congress filed the first-ever legislation to federally decriminalize possession of illicit substances.

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Photo courtesy of Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Congress To Vote On Marijuana, Psychedelics And CBD Amendments This Week Following Committee Action

Published

on

A key House committee on Monday cleared a series of cannabis and psychedelics-related amendments for floor votes as part of large-scale spending legislation. That floor action could happen as soon as Tuesday.

However, the panel also blocked two measures on housing protections for cannabis consumers that legalization supporters hoped to see advance.

One of the most notable amendments the House Rules Committee allowed to move forward for possible attachment to appropriations legislation would remove a rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine.

The reform measure is being sponsored by Rep. Alexandria Ocasio-Cortez (D-NY), and it targets 1990s-era provision that’s long been part of spending legislation for the Department of Health and Human Services (HHS). The congresswoman attempted to eliminate the language via an amendment in 2019 only to have it defeated by Republicans as well as a majority of her party. But it’s far from the only measure being proposed this appropriations season when it comes to drug policy matters.

Some are being backed by reform advocates, while others have received sharp criticism.

One pro-reform amendment that’s advancing would encourage the Food and Drug Administration (FDA) to approve rules allowing CBD as a dietary supplement and food ingredient.

On the other side, there is a proposal from Rep. Debbie Lesko (R-AZ) to the HHS appropriations bill to eliminate a rider that’s currently in the bill that “allows federal funding to go to institutions of higher education that are conducting research on marijuana.”

The reason this measure has generated particular pushback is because research into cannabis is an overwhelmingly bipartisan issue, and top federal drug officials have repeatedly urged Congress to support policies that make it easier to study the risks and benefits of the plant. What’s more, Lesko represents a state with adult-use legalization on the books.

Activists are disappointed that two marijuana reform measures from Rep. Eleanor Holmes Norton (D-DC) are being blocked from floor consideration. Her proposals—which were aimed at appropriations legislation for the Department of Housing and Urban Development (HUD)—would have made it so marijuana possession or consumption could not be used as the sole basis for denying people access to public housing. One Norton amendment was narrowly focused on medical cannabis while a second measure would have covered all marijuana use that’s legal under state laws.

“It’s disappointing that those who rely on public support for housing will continue to be discriminated against for their state-legal choices,” NORML Political Director Justin Strekal told Marijuana Moment.

Advocates were surprised that the Rules Committee, chaired by marijuana reform supporter Rep. James McGovern (D-MA), sought to prevent a floor vote on the Norton cannabis amendments.

A committee spokesperson told Marijuana Moment that the proposals “had points of order against them and we never make amendments in order with points of order against them.”

Here are the descriptions of measures that the Rules Committee made in order for floor votes: 

Rep. Alexandria Ocasio-Cortez (D-NY): Allows United States researchers to study and examine the potential impacts of several schedule I drugs, such as MDMA, psilocybin, and or ibogaine, that have been shown to be effective in treating critical diseases.

Rep. Kurt Schrader (D-OR): Increases and decreases by $5 million, funding for the Center for Food Safety and Applied Nutrition at the FDA, to highlight the need for the Agency to proceed with rulemaking on cannabidiol (or CBD) by no later than 180 days after enactment, out of concern that the FDA has not initiated rulemaking to establish a regulatory pathway for CBD as a dietary supplement and food ingredient.

Rep. Debbie Lesko (R-AZ): Strikes language that allows federal funding to go to institutions of higher education that are conducting research on marijuana.

Rep. Doug LaMalfa (R-CA): Transfers $25 million from the Environmental Programs and Management enforcement activities account to the National Forest System account for enforcement and remediation of illegal marijuana trespass grow sites on federal lands and for the clean-up of toxic waste and chemicals at these sites.

Here are the amendments that were not ruled in order and are thus dead: 

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of marijuana in federally assisted housing in states where marijuana is legal.

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of medical marijuana in federally assisted housing in states where medical marijuana is legal.

Rep. Doug LaMalfa (R-CA): Prohibits funds from this section from being used to fund needle distribution programs for illegal drugs.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use in DC.

Rep. French Hill (R-AR): Increases funding by $50 million for the Office of National Drug Control Policy’s High Intensity Drug Trafficking Areas Program. Offsets the increase with a decrease in funding of $50 million for the Electric Vehicles Fund.


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Overall, these amendments were targeted for inclusion in an appropriations “minibus” bill for fiscal year 2022 to fund the Departments of Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development.

The spending package that is now heading to the House floor for votes on Tuesday also, under its language as originally introduced in appropriations subcommittees, would allow Washington, D.C. to use its local tax dollars to implement a system of lawful marijuana sales for adults.

That stands in contrast to a budget proposal from President Joe Biden, whose administration is seeking to keep language protecting medical cannabis states from federal intervention but has excluded the provision on giving D.C. autonomy to legalize marijuana commerce.

Another provision that was added as part of the Financial Services and General Government (FSGG) spending bill would protect banks that work with marijuana businesses. Further, the committee report attached to that legislation encourages federal government agencies to reconsider policies that fire employees for using marijuana in compliance with state law.

Federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions, a report attached to separate spending legislation that’s part of the advancing minibus package says.

Report language also directs the U.S. Department of Veterans Affairs (VA) to improve communication on veteran eligibility for home loans and report back to Congress on its progress within 180 days of the enactment of the legislation. A separate provision urges VA to expand research on the medical benefits of cannabis for veterans.

In the report for Agriculture Department funding, lawmakers took issue with the 2018 Farm Bill’s 0.3 percent THC cap for lawful hemp products and directed USDA to work with the U.S. Department of Health and Human Services (HHS) and DEA on a study of whether that threshold is scientifically backed. That report also addressed numerous other issues related to the crop.

Other report language attached to this spending package highlights the difficulty of studying Schedule I drugs like marijuana, recognizes the medical potential of cannabinoids like CBD, encourages federal agencies not to restrict the plant kratom and acknowledges the lifesaving value of syringe access programs and safe consumption sites for illegal drugs.

The appropriations process this session has seen numerous drug policy reform provisions included in bill text and attached reports—also stopping immigrants from being deported for cannabis, for example, among other issues.

A bipartisan group of congressional lawmakers recently circulated a letter to build support for an amendment to a separate Department of Justice spending bill that would protect all state and tribal marijuana programs from federal interference—going beyond the existing measure that shields only medical cannabis states that’s currently enacted into law. There are now 15 cosponsors signed on to the broader proposal, which is expected to be considered by the Rules Committee and then potentially see floor action this week.

The Commerce, Justice, Science, and Related Agencies (CJS) spending report also notes that the Drug Enforcement Administration (DEA) has moved to approve additional marijuana manufacturers for research purposes and says the committee supports ongoing research efforts on cannabis, particularly in the wake of an outbreak of lung injuries associated with unregulated vaping products.

A provision was also attached to the bill that would make states and localities ineligible for certain federal law enforcement grants if they maintain a policy allowing for no-knock warrants for drug-related cases. That policy garnered national attention following the police killing of Breonna Taylor, who was fatally shot by law enforcement during a botched drug raid.

The Rules Committee is set to take up CJS and other appropriations legislation on Tuesday.

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment